• 
• 
• 

FDA News and Drug Updates

Welcome to the Third Annual Oncology Guide to New FDA Approvals

FDA Approvals in 2017 Represent a 21-Year High

FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017

Supportive Care

Supportive Care Updates from ASCO 2017 Highlighted at New Orleans Summer Cancer Meeting

Meg Barbor, MPH

A Taxing Consequence: Taxane Acute Pain Syndrome

Mark L. Zangardi, PharmD, BCOP

Helping Adolescents and Young Adults Confront Mortality

Meg Barbor, MPH

View All Supportive Care Articles

Lung Cancer

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC

CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker

View All Lung Cancer Articles

Conference Correspondent

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference

Silent Patients Find Their Voices Through an Advocate’s Journey

View All Conference Correspondent Articles

Most Popular Articles

A Payer’s Perspective on CDK4/6 Inhibitors

Kenneth L. Schaecher, MD, FACP, CPC

March 2018, Supplement - Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

A Nurse Navigator’s Perspective on CDK4/6 Inhibitors

Sharon S. Gentry, RN, MSN, CBCN, CBEC, ONN-CG

March 2018, Supplement - Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

A Pharmacist’s Perspective on CDK4/6 Inhibitors

Robert C. Wolf, PharmD

March 2018, Supplement - Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

March 2018, Supplement - Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer